Mutations in p53 occur in about 90% of the cases in its central DNA-binding domain (DBD), thereby leading to loss of its transactivation properties that are often associated with its tumor-suppressor functions [reviewed in Ref. The gene discussed is TP53; the disease is neoplasm.